DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Estrogen Receptor Positive (ER+) Breast Cancer - Treatment Landscape & Competitive Analysis - 2017" report to their offering.
Estrogen Receptor Positive (ER+) Breast Cancer - Treatment Landscape & Competitive Analysis, 2017 provides comprehensive insights about the treatment landscape across this indication.
This report also provides the deep understanding of the stages of the Estrogen Receptor Positive (ER+) Breast Cancer, epidemiology, risk factors, diagnosis etc. A key objective of the report is to establish the understanding of the treatment landscape and competitive analysis of the Estrogen Receptor Positive (ER+) Breast Cancer which mainly describes the treatment of breast cancer at different stages.
This report provides the insights of the marketed drugs for the Estrogen Receptor Positive (ER+) Breast Cancer which includes the Targeted Therapy, Hormone Therapy and Chemotherapy. In case of Estrogen Receptor Positive (ER+) Breast Cancer, Hormone therapy is the main focus of treatment after surgery and chemotherapy.
Hormonal therapy is usually recommended after 5 years of surgery and can be divided into Estrogen blocking hormonal therapy and estrogen lowering hormonal therapy based on the mechanism of action of the hormonal therapy drugs. Of all the late-stage pipeline drugs, Buparlisib is expected to reach the market in the next few years.
Key Topics Covered:
- Disease Introduction
- Types Of Breast Cancer
- Staging of Breast Cancer
- Risk Factors
- Survival Rates
- Treatment Landscape
- Treatment Algorithm
- Treatment By Stages
- Current medications in Practice
- Treatment for Premenopausal Women
- Treatment for Postmenopausal Women
- Treatment Follow-Up
- Market Drivers
- Market Barriers
- Marketed Products Analysis
- Market Analysis By Type Of Therapy
- Market Analysis By Launch Date, Annual Sales and Patent Expiry
- Marketed Products Profile
- Hormone Therapy
- Late Stage Pipeline Product Analysis
- Current Unmet Needs
For more information about this report visit http://www.researchandmarkets.com/research/vb5nxh/estrogen_receptor